Modality
mAb
MOA
PRMT5i
Target
EGFR
Pathway
Neuroinflam
MCLNSCLCLN
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
Jul 2021
→ Mar 2025
Phase 1Current
NCT08717377
898 pts·MCL
2025-07→2025-03·Active
NCT05464999
1,154 pts·LN
2021-07→TBD·Recruiting
2,052 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-03-071.1y agoPh2 Data· MCL
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1/2
Recruit…
P1/2
Active
Catalysts
Ph2 Data
2025-03-07 · 1.1y ago
MCL
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08717377 | Phase 1/2 | MCL | Active | 898 | CR |
| NCT05464999 | Phase 1/2 | LN | Recruiting | 1154 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C |